We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Ezetimibe (Zetia) — cholesterol-absorption inhibitor
A prescription oral cholesterol-absorption inhibitor (Zetia) that blocks the intestinal NPC1L1 sterol transporter, lowering LDL-C ~15–20% on its own and more when added to a statin. In IMPROVE-IT (~18,000 post-ACS patients) ezetimibe added to simvastatin cut cardiovascular events — the first proof a non-statin LDL-lowering drug improves outcomes. Very well tolerated; rare myalgia and small liver-enzyme rise. Prescription drug, not a supplement.
Prescription medication — not a dietary supplement
Ezetimibe (Zetia) is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Ezetimibe (Zetia) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2003–2026 with a typical study size of 9,438 participants.
Based on 209 studies · 52 meta-analyses · 151 RCTs · 29,455 total participants
Confidence
High confidenceBy outcome
Ezetimibe has strong human evidence: a clear NPC1L1 mechanism, consistent LDL-lowering across RCTs, and the IMPROVE-IT outcome trial showing added cardiovascular benefit when combined with a statin — the first such proof for a non-statin. The score is tempered by a modest monotherapy effect and its strongest outcome data being as a statin add-on rather than stand-alone.
210 rigorous studies
152 randomized trials · 54 meta-analyses · 36 systematic reviews
Our evidence rating for Ezetimibe (Zetia) is accountable to this entire body of rigorous research indexed in PubMed — not a hand-picked subset.
PubMed · as of Jul 2026
5 trials ongoing or recruiting · 109 completed on ClinicalTrials.gov
47 of the completed trials have posted results
Registered trials show research momentum for Ezetimibe (Zetia), not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Aug 2026
Ezetimibe is an oral cholesterol-absorption inhibitor that blocks the Niemann-Pick C1-Like 1 (NPC1L1) sterol transporter on the brush border of intestinal enterocytes, reducing the absorption of dietary and biliary cholesterol.
This lowers cholesterol delivery to the liver, up-regulates hepatic LDL receptors, and clears LDL-C from the blood — a mechanism complementary to and distinct from statins (which block cholesterol synthesis).
As monotherapy ezetimibe lowers LDL-C roughly 15–20%; added on top of a statin it provides a further ~20% reduction, which is why it is most often combined (Vytorin = ezetimibe + simvastatin; Nexlizet = ezetimibe + bempedoic acid).
The landmark outcome trial, IMPROVE-IT (NEJM 2015, ~18,000 patients after acute coronary syndromes), showed that ezetimibe added to simvastatin significantly reduced major cardiovascular events versus simvastatin alone — the first demonstration that a non-statin LDL-lowering drug improves clinical outcomes, reinforcing the 'lower LDL is better' principle.
Supporting trials include SHARP (ezetimibe + simvastatin in chronic kidney disease) and SEAS (in aortic stenosis), and a Cochrane review confirms modest event reductions.
The honest distinction: as monotherapy the LDL effect is real but modest, and its strongest outcome evidence is as an add-on to a statin rather than as a stand-alone therapy. Ezetimibe is very well tolerated — generally comparable to placebo — with only rare myalgia and small, usually transient liver-enzyme elevations.
It is a prescription drug and is presented here for informational purposes only, not as a recommendation; the score reflects genuinely strong human LDL and cardiovascular-outcome evidence against a modest monotherapy effect.
Blocks the intestinal Niemann-Pick C1-Like 1 sterol transporter, reducing absorption of dietary and biliary cholesterol from the gut.
Less cholesterol reaches the liver, so hepatic LDL receptors increase and clear more LDL-C from the blood.
Inhibits absorption rather than synthesis, so combining with a statin (which blocks synthesis) produces additive LDL lowering.
How Ezetimibe (Zetia) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Often a good fit as monotherapy or with a low statin dose — tolerability is close to placebo.
Not recommended — exposure is increased and data are limited.
Avoid, particularly in combination with a statin.
Reduce ezetimibe absorption; separate dosing by several hours.
Additive LDL lowering (intended); very rare additive myopathy/liver-enzyme risk.
Raises ezetimibe (and cyclosporine) blood levels; monitor closely.
May increase cholesterol in bile and gallstone risk; gemfibrozil raises ezetimibe levels.
Tip: Usually mild; more likely when combined with a statin. Report persistent or severe muscle pain.
Tip: Small, usually transient transaminase rise, mainly in statin combinations; periodic liver-function monitoring.
Tip: Generally self-limiting; take with food if it helps.
Tip: Very rare, mainly with concomitant statins; seek care for severe muscle pain with dark urine.
Ezetimibe (Zetia) has an evidence score of 4.4/10 — emerging evidence based on 39 indexed studies. A prescription oral cholesterol-absorption inhibitor (Zetia) that blocks the intestinal NPC1L1 sterol transporter, lowering LDL-C ~15–20% on its own and more when added to a statin. In IMPROVE-IT (~18,000 post-ACS patients) ezetimibe added to simvastatin cut cardiovascular events — the first proof a non-statin LDL-lowering drug improves outcomes. Very well tolerated; rare myalgia and small liver-enzyme rise. Prescription drug, not a supplement. Representative study: PMID 30480766.
The commonly studied dose of Ezetimibe (Zetia) is 10 mg once daily, with or without food, alone or added to a statin — under a clinician. A prescription drug; not a self-directed supplement regimen.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for Ezetimibe (Zetia) — consistent daily use matters more than the time of day. Can be taken at any time of day with or without food; separate from bile-acid sequestrants, which bind it.
Ezetimibe (Zetia) is generally safe at recommended doses, with a few precautions worth noting. The most commonly reported side effects are myalgia (muscle aches), elevated liver enzymes, diarrhea / abdominal discomfort. Use caution if any of these apply to you: Active liver disease or unexplained persistent transaminase elevations (when combined with a statin); Pregnancy and breastfeeding (especially in combination with a statin); Known hypersensitivity to ezetimibe.
Pioglitazone (Actos)
Mostly mechanism / observationalAn oral thiazolidinedione (Actos) diabetes drug that improves insulin sensitivity via PPAR-gamma. It drew geroscience interest after reducing recurrent stroke/MI in insulin-resistant non-diabetics (IRIS) and improving NASH liver histology — but weight gain, fluid retention / heart-failure risk, fracture risk, and a debated bladder-cancer signal keep enthusiasm in check. Prescription drug, not a supplement.
CoQ10
Likely helpsA lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.
Red Yeast Rice
Likely helpsFermented rice containing natural statins that effectively lower LDL cholesterol — the original statin.
Berberine
Likely helpsActivates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism — comparable to metformin in some trials.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 209 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research